polyneuropathy

(redirected from Familial amyloid polyneuropathy)
Also found in: Dictionary, Wikipedia.
Related to Familial amyloid polyneuropathy: Amyloid angiopathy

polyneuropathy

 [pol″e-noo͡-rop´ah-the]
a disease involving several nerves.
amyloid polyneuropathy polyneuropathy caused by amyloidosis; symptoms may include dysfunction of the autonomic nervous system, carpal tunnel syndrome, and sensory disturbances in the extremities.
familial amyloid polyneuropathy autosomal dominant amyloid polyneuropathy occurring in hereditary amyloidosis; subtypes include Finnish type, Indiana type, Iowa type, and Portuguese type. The Finnish and Indiana types are slowly progressive, whereas in the Portuguese and Iowa types death may occur within 7 to 10 years.
erythredema polyneuropathy acrodynia.

pol·y·neu·rop·a·thy

(pol'ē-nū-rop'ă-thē),
1. A disease process involving a number of peripheral nerves (literal sense).
2. A nontraumatic generalized disorder of peripheral nerves, affecting the distal fibers most severely, with proximal shading (for example, the feet are affected sooner or more severely than the hands), and typically symmetrically; most often affects motor and sensory fibers almost equally, but can involve either one, either solely or very disproportionately; classified as axon degenerating (axonal), or demyelinating; many causes, particularly metabolic and toxic; familial or sporadic. Synonym(s): polyneuritis
[poly- + G. neuron, nerve, + pathos, disease]

polyneuropathy

/poly·neu·rop·a·thy/ (-ndbobr-rop´ah-the) neuropathy of several peripheral nerves simultaneously.
amyloid polyneuropathy  polyneuropathy associated with amyloidosis, of either the primary or the familial type; symptoms may include dysfunction of the autonomic nervous system, carpal tunnel syndrome, and sensory disturbances in the limbs.
erythredema polyneuropathy  acrodynia.
familial amyloid polyneuropathy  autosomal dominant amyloid polyneuropathy, associated with familial amyloidosis and most commonly involving a mutant form of the protein transthyretin.; it may be subclassified on the basis of affected kinships or on the basis of symptoms and the biochemical composition of the affected fibrils.

polyneuropathy

(pŏl′ē-no͝o-rŏp′ə-thē)
n.
Neuropathy involving several peripheral nerves.

polyneuropathy

[-noo͡rop′əthē]
Etymology: Gk, polys, many, neuron, nerve, pathos, disease
a condition in which many peripheral nerves are afflicted with a disorder.

polyneuropathy

Chronic inflammatory polyneuropathy, critical illness polyneuropathy, familial amyloidotic polyneuropathy, multiple neuropathy, peripheral neuropathy, polyneuritis, sensorimotor polyneuropathy Neurology The simultaneous inflammation of the motor and/or sensory components of 2 or more peripheral nerves. See Mononeuropathy.

pol·y·neu·rop·a·thy

(pol'ē-nūr-op'ă-thē)
1. A disease process involving a number of peripheral nerves (literal sense).
2. A nontraumatic generalized disorder of peripheral nerves, affecting the distal fibers most severely, with proximal shading (e.g., the feet are affected sooner or more severely than the hands), and typically symmetrically; most often affects motor and sensory fibers almost equally, but can involve either one solely or very disproportionately; classified as axon degenerating (axonal) or demyelinating; many causes, particularly metabolic and toxic; familial or sporadic in nature.
Synonym(s): polyneuritis.
3. Synonym(s): acrodynia (2) . Synonym(s): multiple neuritis.
[poly- + G. neuron, nerve, + pathos, disease]

polyneuropathy

generalized autonomic, sensory and motor neuropathy; characteristic of late-stage diabetes mellitus

pol·y·neu·rop·a·thy

(pol'ē-nūr-op'ă-thē)
1. Disease process involving several peripheral nerves (literal sense).
2. Nontraumatic generalized disorder of peripheral nerves, affecting distal fibers most severely, with proximal shading.
[poly- + G. neuron, nerve, + pathos, disease]

polyneuropathy

a disease involving several nerves. See also neuropathy.

acute idiopathic polyneuropathy
see idiopathic polyradiculoneuritis.
distal polyneuropathy of Birman cats
a noninflammatory, diffuse loss of myelinated fibers in the distal portions of the central and peripheral nervous systems, resulting in progressive hindlimb ataxia and hypermetria in young Birman kittens. Believed to be inherited as an autosomal recessive trait.
familial polyneuropathy
see Boxer progressive axonopathy, hereditary neuronal abiotrophy of Swedish Lapland dogs, giant axonal neuropathy.
hypoglycemic polyneuropathy
associated with hyperinsulinism of β-cell insulinomas; there is generalized muscle weakness, paraparesis and tetraparesis.
hypothyroid polyneuropathy
a progressive lower motor neuron disease associated with hypothyroidism.
idiopathic polyneuropathy
see idiopathic polyradiculoneuritis.
immune-mediated polyneuropathy
may occur in association with systemic lupus erythematosus in dogs.
References in periodicals archive ?
Rx] in patients with familial amyloid polyneuropathy (FAP).
Changes in renal function in patients with familial amyloid polyneuropathy treated with orthotopic liver transplantation.
Improvement in the polyneuropathy associated with familial amyloid polyneuropathy after liver transplantation.
A snapshot of the global therapeutic scenario for Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease).
Tafamidis is a novel, investigational medication for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) in adult patients with symptomatic polyneuropathy to delay neurologic impairment.
Rx] is currently being evaluated in a Phase 3 randomized, double-blind, placebo-controlled, international study in patients with familial amyloid polyneuropathy (FAP).
Keio University Hospital surgeons removed the liver of a patient in his 20s with familial amyloid polyneuropathy (FAP), a slowly progressive disease that can eventually be fatal.
Tafamidis is a novel, investigational, oral therapy for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) in adult patients with symptomatic polyneuropathy to delay neurologic impairment.
The company's three lead, late stage products are for treatment of sickle cell anemia, transthyretin familial amyloid polyneuropathy (TTR-FAP), and neurocysticercosis (NCC).
Monday at the Keio hospital, where a liver was removed from a patient in his 20s suffering from familial amyloid polyneuropathy (FAP), a slowly progressive disease that can be fatal.
Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for tafamidis meglumine, the company's investigational, novel, oral therapy for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP).
Rx] in Patients with Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP): Study Design and Baseline Demographics', Dr.

Full browser ?